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background: In primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI), the relative safety 
of drug-eluting stents (DES) versus bare metal stents (BMS) continues to be debated. Whilst DES use is associated with reduced target lesion 
revascularization rates, stent thrombosis continues to be a major concern. We compared the effect of DES vs. BMS on 1-year mortality in patients 
with STEMI undergoing primary PCI.
methods: We conducted an observational analysis for patients with STEMI who underwent PPCI between 2004-2011 at all 8 tertiary cardiac 
centres in London, UK. The primary outcome was all-cause mortality at 1 year. We used 4 analytic methods to adjust for selection bias: multivariate 
Cox proportional hazards regression; propensity-based matching; inverse probability weighted analysis and instrumental variable analysis.
results: Of the 10,803 patients in the analysis, 4239 patients (39%) received DES and 6564 patients received BMS (61%). The following DES were 
used: paclitaxel-eluting stent (PES), 16.5%; sirolimus-eluting stent (SES), 26.4%; everolimus-eluting stent (EES), 19.9%; zotaralimus-eluting stent 
(ZES), 21.8%; or other stent, 19.5%. 1-year mortality was similar between both groups (BMS vs. DES: 7.9% vs. 7.6%, p=0.630). Multivariate analyses 
demonstrated that DES use did not affect mortality (HR=0.99, 95% CI:0.82-1.20, p=0.991). This was confirmed in propensity-matched cohorts with 
5506 patients (HR=0.95, 95% CI:0.76-1.19, p=0.667) and inverse probability weighted analyses (HR=1.08 , 95% CI: 0.85-1.36, p=0.533). Using 
enrollment year as an instrumental variable, DES use did not affect mortality (absolute difference=-0.26, 95% CI:-4.08,3.57, p=0.896). Propensity-
matched analyses demonstrated no difference in mortality when comparing the different DES with BMS: PES (HR=1.43, 95% CI:0.79-2.57, p=0.231); 
EES (HR=1.19, 95% CI:0.82-1.72, p=0.355); SES (HR=0.81, 95% CI:0.53-1.23, p=0.325); and ZES (HR=0.75, 95% CI:0.50-1.11, p=0.154).
Conclusions: In this observational analysis of patients with STEMI undergoing PPCI, DES appear to have a similar safety compared to BMS with no 
difference in mortality at 1 year.
